Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer.

Timothy J Brown,Thomas Benjamin Karasic,Charles Schneider,Ursina R. Teitelbaum,Kim A. Reiss,Tara C. Mitchell,Ryan Massa,Mark H. OHara,Lisa DiCicco,Luis Garcia-Marcano,Ravi K. Amaravadi,Peter J. ODwyer

Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer.

2021

Timothy J Brown
Thomas Benjamin Karasic
Charles Schneider
Ursina R. Teitelbaum
Kim A. Reiss
Tara C. Mitchell
Ryan Massa
Mark H. OHara
Lisa DiCicco
Luis Garcia-Marcano
Ravi K. Amaravadi
Peter J. ODwyer

e15580Background: The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer. Antiangiogenic therapy cause...

Keywords:

Tyrosine-kinase inhibitor
Internal medicine
Medicine
Oncology
Colorectal cancer
in patient
Hydroxychloroquine
antiangiogenic therapy
Regorafenib
previously treated
Entinostat

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations